
Loading, please wait...

Loading, please wait...

Neuromyelitis optica spectrum disorder represents a severe autoimmune inflammatory astrocytopathy that classically targets the optic nerves and spinal cord. Neurologists typically expect extensive spinal cord lesions on neuroimaging during acute myelopathic episodes. However, emerging evidence highlights that acute MRI-negative myelitis can occasionally manifest as the initial presentation of aquaporin-4 antibody-positive disease. Consequently, this rare clinical scenario presents severe diagnostic challenges for treating physicians. When structural neuroimaging reveals normal findings despite objective neurological deficits, physicians may hesitate to initiate aggressive immunotherapies. Therefore, understanding this occult manifestation ensures timely intervention and prevents devastating long-term neurological disability.
Acute transverse myelitis typically presents with rapidly progressive paraparesis, sensory impairment, and autonomic dysfunction. In neuromyelitis optica spectrum disorder, spinal magnetic resonance imaging usually reveals longitudinally extensive lesions spanning three or more vertebral segments. However, a recent case report documented a 51-year-old female presenting with subacute myelopathy who exhibited completely normal spinal neuroimaging. Consequently, the absence of radiographically detectable parenchymal signal alterations created significant diagnostic confusion.
Physicians frequently rely on conventional T2-weighted and contrast-enhanced sequences to substantiate inflammatory central nervous system pathology. When spinal imaging shows no abnormal signal intensity or swelling, clinicians may question the organic nature of the symptoms. Furthermore, clinicians often contemplate non-inflammatory causes such as acute ischemia, metabolic deficiencies, or structural compression syndromes. In this atypical presentation, the patient suffered from progressive sensorimotor deficits without visible structural abnormalities. Therefore, relying exclusively on neuroimaging can delay critical diagnosis. Clinicians must recognize that acute autoimmune myelopathy may exist beneath radiological detection thresholds. Notably, maintaining a heightened index of suspicion whenever patients exhibit clear central myelopathic signs remains vital for patient outcomes.
When neuroimaging fails to reveal structural spinal lesions, electrophysiological assessments provide objective functional data. In this pivotal clinical scenario, neurophysiologists performed somatosensory evoked potentials and motor evoked potentials to evaluate spinal cord integrity. These functional investigations confirmed marked central conduction failure, directly establishing true intrinsic spinal cord pathway dysfunction. Consequently, electrophysiology successfully bridged the gap between normal radiological images and progressive clinical deficits.
Somatosensory evoked potentials evaluate dorsal column integrity by assessing central conduction time from peripheral stimulation sites to the cerebral cortex. Similarly, motor evoked potentials assess descending corticospinal tract pathway integrity through transcranial magnetic stimulation. In addition, these electrophysiological modalities identify subclinical pathway disruption with exceptional sensitivity. Evoked potentials often detect microscopic conduction blocks before parenchymal edema or macroscopic demyelination becomes evident on standard imaging. Therefore, neurophysiological testing remains an indispensable diagnostic tool for investigating suspected myelopathies with unrevealing spinal imaging. Importantly, by confirming impaired central conduction velocity, clinicians can confidently pursue targeted immunological workups and avoid dangerous therapeutic delays.
Neuromyelitis optica spectrum disorder is primarily an autoimmune astrocytopathy rather than a pure demyelinating disease. Pathogenic immunoglobulin G autoantibodies target aquaporin-4 water channels abundantly expressed on astrocytic foot processes. This antibody binding triggers complement-dependent cytotoxicity, secondary granulocyte infiltration, and subsequent oligodendrocyte loss. However, the initial pathophysiological phase may cause severe cellular dysfunction and metabolic disruption without macroscopic fluid accumulation or extensive tissue necrosis.
Standard magnetic resonance imaging sequences primarily detect abnormal water distribution, blood-brain barrier breakdown, and tissue edema. If the autoimmune attack induces functional astrocytopathy without gross vasogenic edema, conventional sequences may fail to visualize the pathology. Furthermore, low lesion burden or focal microvascular disturbances can evade detection on standard scanners. In such circumstances, serological confirmation using cell-based assays provides definitive diagnostic evidence. Highly specific serum aquaporin-4 immunoglobulin G confirms the underlying autoimmune etiology regardless of imaging findings. Thus, cellular-level astrocytic dysfunction can cause profound clinical conduction blocks before visible cord changes emerge on neuroimaging.
The sudden emergence of motor and sensory deficits alongside normal neuroimaging requires comprehensive differential diagnosis. Initially, clinicians frequently misclassify such presentations as functional neurological disorder. However, attributing objective physical signs like hyperreflexia, extensor plantar responses, or sensory levels to non-organic disease introduces grave clinical risks. Therefore, physicians must systematically evaluate both inflammatory and non-inflammatory alternative etiologies.
First, clinicians must exclude spinal cord ischemia, which may initially show normal diffusion-weighted imaging before infarction matures. Second, clinicians must assess metabolic myelopathies, including vitamin B12 deficiency, copper deficiency, and nitrous oxide toxicity. Third, infectious myelitis caused by enteroviruses, herpesviruses, or tuberculosis warrants thorough cerebrospinal fluid analysis. Furthermore, autoimmune conditions such as myelin oligodendrocyte glycoprotein antibody-associated disease, systemic lupus erythematosus, and neurosarcoidosis can involve the spinal cord. Nevertheless, the definitive identification of serum aquaporin-4 autoantibodies confirms neuromyelitis optica spectrum disorder, guiding targeted immunosuppressive therapy while eliminating confounding differential diagnoses.
Rapid initiation of acute immunotherapy is essential to prevent permanent functional disability in neuromyelitis optica spectrum disorder. Clinicians must administer high-dose intravenous methylprednisolone, typically one gram daily for three to five consecutive days. If patients exhibit inadequate clinical recovery, physicians should promptly institute therapeutic plasma exchange or intravenous immunoglobulin. Delaying acute intervention while awaiting repeat imaging can cause irreversible axonal destruction and severe permanent disability.
Following acute stabilization, clinicians must initiate long-term maintenance immunosuppression to prevent catastrophic relapses. Historically, clinicians utilized broad immunosuppressive agents such as azathioprine, mycophenolate mofetil, and rituximab. However, modern targeted biologic therapies have revolutionized disease prevention in aquaporin-4-positive patients. Specifically, complement inhibitors such as eculizumab, interleukin-6 receptor antagonists such as satralizumab, and anti-CD19 monoclonal antibodies such as inebilizumab offer superior relapse reduction. Crucially, clinicians must avoid multiple sclerosis disease-modifying therapies, including interferon-beta, fingolimod, and natalizumab, because these medications exacerbate aquaporin-4-mediated disease. Therefore, establishing an accurate molecular diagnosis directly dictates lifesaving long-term maintenance therapy for every patient.
MRI-negative myelitis in neuromyelitis optica spectrum disorder describes acute inflammatory spinal cord dysfunction occurring without visible abnormalities on conventional magnetic resonance imaging. Although the disease classically produces longitudinally extensive spinal cord lesions, rare patients exhibit profound motor or sensory deficits despite normal neuroimaging. In these unique cases, pathogenic aquaporin-4 autoantibodies cause cellular astrocytic dysfunction and conduction block before macroscopic tissue edema or structural necrosis develops on scans.
Clinicians establish the diagnosis by combining thorough physical examination, objective neurophysiological studies, and serological testing. Somatosensory and motor evoked potentials play a crucial role by identifying central conduction delays across spinal tracts. Additionally, clinicians analyze cerebrospinal fluid to detect inflammatory pleocytosis or elevated protein. Finally, detecting serum aquaporin-4 antibodies via sensitive cell-based assays confirms the autoimmune etiology, even in the absence of radiographically detectable structural lesions.
Early diagnosis is vital because acute attacks of aquaporin-4-positive myelitis cause severe, cumulative neurological disability. Prompt administration of high-dose corticosteroids or therapeutic plasma exchange salvages vulnerable neural tissue and optimizes functional recovery. Furthermore, securing an accurate diagnosis ensures the immediate introduction of targeted maintenance immunosuppression to prevent recurrent attacks. Importantly, misidentifying the disorder as multiple sclerosis leads to inappropriate therapies that can severely exacerbate the underlying disease.
Disclaimer: This content is for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Qualified healthcare providers must exercise independent clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A recent report identifies MRI-negative myelitis as an atypical presentation of AQP4-IgG positive neuromyelitis optica spectrum disorder. Normal neuroimaging must not delay diagnosis; evoked potentials and serological testing enable prompt targeted immunotherapy to avert permanent neurological damage.
Today

A groundbreaking Bayesian two-stage clinical trial design integrates historical reference data using MAP priors to evaluate biosimilarity and interchangeability efficiently, minimizing patient burden in rheumatoid arthritis studies.
Today

A qualitative study in the Journal of Human Lactation highlights the significant hurdles healthcare workers face when continuing breastfeeding. Inadequate facilities, rigid shift schedules, and lack of institutional policies demand structured workplace lactation support and compliant hospital infrastructure.
Today

A cross-sectional study evaluates the critical intersection between acute surgical pain, kinesiophobia, and fall risks during initial mobilization after cardiac surgery, emphasizing targeted nursing strategies.
Today

A recent cross-sectional analysis reveals that over a quarter of randomized controlled trials for non-specific low back pain face discontinuation or unknown status, while more than 36% of completed trials remain unpublished, exposing notable reporting gaps in spine and musculoskeletal clinical research.
Today

Explore revascularisation strategies in dialysis-dependent chronic limb-threatening ischaemia. This review examines surgical bypass vs endovascular therapy, BEST-CLI trial findings, procedural morbidity, conduit availability, and multidisciplinary decision-making for optimal limb salvage.
Today